Infrapatellar Fat Pad:An Alternative Source of Adipose-Derived Mesenchymal Stem Cells by Tangchitphisut, P et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Infrapatellar Fat Pad
Citation for published version:
Tangchitphisut, P, Srikaew, N, Numhom, S, Tangprasittipap, A, Woratanarat, P, Wongsak, S,
Kijkunasathian, C, Hongeng, S, Murray, IR & Tawonsawatruk, T 2016, 'Infrapatellar Fat Pad: An Alternative
Source of Adipose-Derived Mesenchymal Stem Cells' Arthritis, vol. 2016, pp. 4019873. DOI:
10.1155/2016/4019873
Digital Object Identifier (DOI):
10.1155/2016/4019873
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Arthritis
Publisher Rights Statement:
Copyright © 2016 P. Tangchitphisut et al. This is an open access article distributed under the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Research Article
Infrapatellar Fat Pad: An Alternative Source of
Adipose-Derived Mesenchymal Stem Cells
P. Tangchitphisut,1 N. Srikaew,2 S. Numhom,3 A. Tangprasittipap,2 P. Woratanarat,1
S. Wongsak,1 C. Kijkunasathian,1 S. Hongeng,4 I. R. Murray,5 and T. Tawonsawatruk1
1Department of Orthopaedics, Faculty of Medicine, Ramathibodi Hospital, Bangkok 10400, Thailand
2Office of Research and Innovation, Ramathibodi Hospital, Bangkok 10400, Thailand
3Department of Surgery, Faculty of Medicine, Ramathibodi Hospital, Bangkok 10400, Thailand
4Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Bangkok 10400, Thailand
5Department of Orthopaedics, Royal Infirmary Edinburgh Hospital, Edinburgh University, Edinburgh, UK
Correspondence should be addressed to T. Tawonsawatruk; tulyapruek@gmail.com
Received 25 November 2015; Revised 7 February 2016; Accepted 14 February 2016
Academic Editor: Changhai Ding
Copyright © 2016 P. Tangchitphisut et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Introduction.The Infrapatellar fat pad (IPFP) represents an emerging alternative source of adipose-derivedmesenchymal stem cells
(ASCs). We compared the characteristics and differentiation capacity of ASCs isolated from IPFP and SC.Materials and Methods.
ASCs were harvested from either IPFP or SC. IPFPs were collected from patients undergoing total knee arthroplasty (TKA),
whereas subcutaneous tissues were collected from patients undergoing lipoaspiration. Immunophenotypes of surface antigens
were evaluated. Their ability to form colony-forming units (CFUs) and their differentiation potential were determined. The ASCs
karyotype was evaluated. Results. There was no difference in the number of CFUs and size of CFUs between IPFP and SC sources.
ASCs isolated from both sources had a normal karyotype. The mesenchymal stem cells (MSCs) markers on flow cytometry was
equivalent. IPFP-ASCs demonstrated significantly higher expression of SOX-9 and RUNX-2 over ASCs isolated from SC (6.19 ±
5.56-, 0.47 ± 0.62-fold; 𝑝 value = 0.047, and 17.33 ± 10.80-, 1.56 ± 1.31-fold; 𝑝 value = 0.030, resp.). Discussion and Conclusion. CFU
assay of IPFP-ASCs and SC-ASCs harvested by lipoaspiration technique was equivalent. The expression of key chondrogenic and
osteogenic genes was increased in cells isolated from IPFP. IPFP should be considered a high quality alternative source of ASCs.
1. Introduction
Thailand has a rapidly ageing society. The population aged
over 65 years has grown markedly over the last decade
[1]. According to a report by the Institute for Population
and Social Research, over 9 million people were considered
elderly in Thailand in 2015, with this increasing by 7 percent
per year over the coming 5 years [1]. As a result, there will
be a parallel increase in degenerative diseases. Osteoarthritis
(OA) is the most common cause of joint diseases [2] with
the knee most commonly affected joint (approximately 50.2
percent) [3]. Progression of OA can result in severe disability,
compromising quality of life [4] and having significant
financial implications for individuals and society. There are
currently no treatments that effectively regenerate cartilage
or delay the progression of OA.
Mesenchymal stem cells (MSCs) derived from bone
marrow have been evaluated in the treatment of OA [5].
A number of studies have demonstrated that MSCs can
be isolated from multiple tissue sources including blood,
bone marrow, adipose tissue, and cartilage [6]. MSCs have
the ability to differentiate into adipocytes, osteocytes, and
chondrocytes, while contributing to a regenerative microen-
vironment through the release of trophic factors [7]. As such,
MSC based approaches may be promising in the treatment
of osteoarthritis. However, there have so far been few well-
designed randomized controlled trials [8, 9], withmany exist-
ing studies evaluating low patient numbers with incomplete
Hindawi Publishing Corporation
Arthritis
Volume 2016, Article ID 4019873, 10 pages
http://dx.doi.org/10.1155/2016/4019873
2 Arthritis
treatment evaluation. Further studies are required before the
widespread application of MSCs in clinical practice. Further-
more, there is ongoing controversy relating to optimizing cell
source, cell preparation conditions, ideal dosing, andmethod
of delivery [5, 10–13].
Cell source is one factor that may influence treatment
outcomes. It has been reported that adipose-derived mes-
enchymal stem cells (ASCs) had more rapid cell doubling
times and antiapoptotic potential when compared to MSCs
from other sources [14]. There have been an increasing
number of studies evaluating ASCs in both experimental and
clinical studies in over the past 10–20 years. Overall these
studies have demonstrated promising results for ASCs in the
management of OA knee and chondral injury [5, 10–12, 15–
19]. Underlying mechanisms have been elucidated including
the release of various cytokines from MSCs that resulted
in anti-inflammatory effects and increased regeneration of
damaged cells [20–24]. MSCs have also resulted in improved
clinical outcomes including knee motion, decreased visual
analog pain scale (VAS), and improved quality of life as
evaluated by the WOMAC index. Stem cell therapy for
knee OA has been found to be safe with no major com-
plications or adverse effects reported in treatments to date
[5, 8, 10–12].
The infrapatellar fat pad (IPFP) is located in the knee
joint [25, 26]. IPFP can be easily resected during knee surgery
either open or arthroscopically [27]. The isolation of MSCs
has previously been reported from this source [28]. However,
there are a few studies comparing the characteristics and
differentiation potentials between ASCs isolated from IPFP
and subcutaneous tissue (SC) [9, 29, 30].
Therefore, this study aimed to evaluate (1) the character-
istics and (2) differentiation abilities of ASCs isolated from
different sources (IPFP versus SC).The safety profiles, includ-
ing bacterial infection and karyotype, were also examined.
Ultimately this study sought to identify the most appropriate
source of ASCs for cell-based treatment of OA knee.
2. Materials and Methods
2.1. Study Design and Patients. This study was designed as an
in vitro experimental study and conducted between Decem-
ber 2014 and April 2015 at Ramathibodi Hospital, Bangkok,
Thailand. It was approved by Committee on Human Rights
Related to Research Involving Human Subjects, Faculty of
Medicine, Ramathibodi Hospital (MURA2014/476). All par-
ticipants provided informed consent before being enrolled to
the study. Five patients aged over 50 years diagnosed with
primary OA (Kellgren-Lawrence (KL) classification 3 or 4)
scheduled for total knee arthroplasty (TKA) were included in
this study for IPFP harvesting. 5 samples of SC were collected
from patients who underwent cosmetic liposuction.
2.2. Infrapatellar Fat Pad Adipose-Derived Mesenchymal Stem
Cells (IPFP-ASCs) Isolation and Culture Technique. IPFPs
were harvested duringTKAwith tissues and then used for cell
isolation. In brief, IPFP tissues were washed with phosphate
buffer solution (PBS), rinsed, and then chopped in small
pieces of about 0.5mm3. Tissues were washed again in 5mL
of PBS two further times. 0.1% collagenase type I (Gibco,
USA) was added and incubated under warm-water bath
(37∘C) for 60 minutes then suspended with Dulbecco’s Mod-
ified Eagle Medium-Low Glucose (DMEM-LG; Biochrom,
Germany) with 10% fetal bovine serum (FBS; Biochrom,
Germany) and centrifuged under 400x for 10 minutes and
surfactant layer was removed. The retained pellet was mixed
with 10mL of PBS, then passed through a sterile filter (Cell
Strainer), and centrifuged at the same speed. The cell pellet
was resuspended in 1mL of complete medium (DMEM-LG +
10% FBS + 1% L-glutamic acid (Gibco, USA) + 1% Penstrep
(Gibco, USA) + 0.1% Amphotericin-B (Fungizone)) and
then divided for cell counting using a hemocytometer. Cells
were then seeded in T-25 tissue culture flasks at a density of
5,000 cell/cm2 at 37∘C (humidified atmosphere 95% O
2
and
5% CO
2
).Themediumwas changed every 2 days. On days 7–
10, the cells were accessed and microscopic appearance was
observed by at least 2 investigators. If cells coveredmore than
80% of the culture flask, thenASCswere detachedwith 0.05%
Trypsin/0.1% EDTA (Gibco, Canada) and recultured as the
first passage with complete medium through 3rd passage.
Cell count and time between each passage were recorded.
MSCs in 3rd passage were trypsinized and divided for cell
phenotypes, safety profiles, and ASCs differentiation assays.
SC was processed as per IPFP for cell isolation and culture
expansion.
2.3. ASCs Immunophenotypes and Safety Profiles Assessment.
Positive cell surface markers (CD 73, CD 90, and CD 105;
eBioscience, USA) andnegative cell surfacemarkers (CD34,
CD 45, and HLA-DR; eBioscience, USA) were evaluated by
flow cytometry.
Individual samples of 1 × 105 cells of ASCs from each
patient were resuspended in 3mL PBS that was sent to
Central Laboratory, Department of Pathology, Ramathi-
bodi Hospital, for evaluation of aerobe/anaerobe bacterium,
mycobacterium, and mycoplasma contamination.
For ASCs karyotype assessment, complete medium was
aspirated from 3rd passage of T-25 flask and 10 𝜇L/mL
Colcemic solution (Gibco, USA) added and incubated for
3.5 hrs to inhibit the cell cycle. 5mLs of PBS solution was
added to wash out Colcemic solution prior to trypsinization
centrifuge pelleting. The pellet was resuspended in 10mL of
0.068M potassium chloride (KCl) solution prior to incuba-
tion for 15minwith gentle cyclic inversion of the tube. Finally,
samples were sent to Genetic Section, Ramathibodi Hospital,
for cell karyotype assessment. At least 2 metaphase cells
were compared for each set of homologues chromosomes
manually [31].
2.4. Colony-Forming Unit (CFU) Assay. ASCs from both
SC and IPFP were seeded in polypropylene 6-well plates,
which 3 different dilutions (100, 250, and 500 cells/well) to
evaluated ASCs proliferation potential. Cells were cultured
under complete media for 14 days; then cells were fixed by
methanol and stained with Giemsa solution. The number of
colonies was then counted under a lightmicroscope (4x).The
largest colonies in each quarter of a culturewell were captured
under 4x microscope and the size of colonies was counted in
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Table 1: Primer sequences.
Gene Sequence forward Sequence reverse
SOX-9 5󸀠AGGTGCTCAAAGGCTACGAC 3󸀠 5󸀠 GTAATCCGGGTGGTCCTTCT 3󸀠
RUNX-2 5󸀠 CGGAATGCCTCTGCTGTTAT 3󸀠 5󸀠 TTCCCGAGGTCCATCTACTG 3󸀠
PPAR-𝛾 5󸀠 CCAGAAAGCGATTCCTTCAC 3󸀠 5󸀠 TGCAACCACTGGATCTGTTC 3󸀠
GAPDH 5󸀠 TGTTGCCATCAATGACCCCTT 3󸀠 5󸀠 CTCCACGACGTACTCAGCG 3󸀠
Table 2: Baseline characteristics of IPFP-ASCs.
Case 1 Case 2 Case 3 Case 4 Case 5
Sex Female Female Female Female Female
Age (yrs) 77 53 71 66 62
BMI (kg/m2) 26.53 27.01 24.44 20.50 20.24
Side of TKA operation Right Right Right Right Right
OA classification Stage 4 Stage 4 Stage 4 Stage 4 Stage 4
Fat pad weight (g) 13.49 8.48 10.25 8.63 14.75
Number of ASCs isolation (P0∗) (×106 cells) 9.10 1.25 6.75 1.43 1.16
Yield of ASCs collection (P0∗) (×104 cells/g) 67.46 9.27 67.79 16.51 7.88
Incubation time (days) 17 28 17 16 14
P0 to P1∗∗ 7 10 10 6 7
P1 to P2∗∗∗ 10 18 7 10 7
∗0th passage.
∗∗1st passage.
∗∗∗2nd passage.
duplicate manner using ImageJ software version 1.48 (NIH,
USA) [32].
2.5. ASCsDifferentiationAbilities Assessment. Chondrogenic,
adipogenic, and osteogenic differentiation potential were
determined. 5 × 106 cells from 3rd passage of IPFP-ASCs
and subcutaneous adipose-derived mesenchymal stem cells
(SC-ASCs) were split and cultured under specific medium
T-25 flask for adipogenic and osteogenic differentiation
but cultured in 6-well plate for chondrogenic differen-
tiation. Time for ASCs culture in specific medium was
21 days.
For chondrogenic differentiation medium, we used com-
mercial medium from PromoCell, USA. Adipogenic and
osteogenic differentiation media were combined with Dul-
becco’s Modified Eagle Medium-Low Glucose (DMEM-
LG), Ham’s-12, 10% FBS, 1% L-glutamic acid, and 1% Pen-
strep. Isobutyl methylxanthine (IBMX; Sigma, Japan), Dex-
amethasone (Sigma, Japan), Insulin (Sigma, Japan), and
Indomethacin (Sigma, China) with based medium were
used for adipogenic differentiation medium. Also, Dexam-
ethasone, 𝛽-glycerophosphate (Sigma, USA), and Ascorbic
Acid (Sigma, Japan) were combined with based medium for
osteogenic differentiation medium.
At day 21, cells were stained to identify cell morphol-
ogy. Chondrogenic-induced ASCs were stained by Alcian
Blue staining solution (staining dark blue for aggrecan).
Osteogenic-induced ASCs were stained using Alizarin Red
staining solution that detected extracellular calcium depo-
sition (bright orange-red). Adipogenic-induced ASCs were
stained using Oil Red-O (intracellular lipid vesicles staining
bright red).
Furthermore, RNA extraction by Trizol technique and
cDNA synthesis (RealMasterScript, SuperMix Kit) were
performed. Real-time polymerase chain (RT-PCR, LightCy-
cler 480 II) was performed for quantitative assessment of
SOX-9, RUNX-2, and PPAR-𝛾 expression that were repre-
sented for chondrogenic, osteogenic, and adipogenic differ-
entiation. Primer sequences of SOX-9, RUNX-2, PPAR-𝛾, and
GAPDH are showed in Table 1.
2.6. Statistical Analysis. Overall 10 ASCs samples (5 samples
from IPFP and the others from SC) were analyzed by SPPS
version 15.0 (IBM, USA). A 𝑝 value < 0.05 was considered
significant in this study. Analysis of variance was calculated
for data comparison in demographic data of patients, MSCs
immunophenotypes, CFUs, and gene expression of ASCs in
each source.
3. Results
3.1. Demographic Data. IPFPs were collected by sterile tech-
nique from 5 female participants undergoing TKA. Patient’s
age ranged from 53 to 77 years, with BMI ranging from 20.24
to 26.53 kg/m2. All participantswere diagnosedwithOA right
knee stage 4 by KL classification. The IPFP was measured for
weight (range 8.48–14.75 g) and for yield for cell extraction
(range 7.88× 104–67.79× 104 cell/g).Mean time for cell culture
from 0th passage to 2nd passage was 18.40 ± 5.50 days (range
14–28 days) (Table 2).
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Table 3: Baseline characteristics of SC-ASCs.
Case 1 Case 2 Case 3 Case 4 Case 5
Sex Male Female Female Female Female
Age (yrs) 32 16 19 48 37
BMI (kg/m2) 17.70 25.65 19.91 36.29 18.03
Fat pad weight (g) 28.30 64.43 63.18 75.85 30.55
Number of ASCs isolation (P0∗) (×106 cells) 2.20 4.10 3.35 2.65 6.65
Yield of ASCs collection (P0∗) (×104 cells/g) 7.78 8.06 5.30 3.49 21.76
Incubation time (days) 22 14 15 33 15
P0 to P1∗∗ 7 7 8 19 7
P1 to P2∗∗∗ 15 7 7 14 8
∗0th passage.
∗∗1st passage.
∗∗∗2nd passage.
Table 4: Comparison of baseline characteristics between IPFP-ASCs and SC-ASCs.
Infrapatellar fat pad
(𝑁 = 5)
𝑛 (%)
Subcutaneous
(𝑁 = 5)
𝑛 (%)
𝑝 value
Gender 1.000†
Male — 1 (20.00)
Female 5 (100.00) 4 (80.00)
Age (yrs)∗ 65.80 ± 9.09 30.40 ± 13.16 0.001
BMI (kg/m2)∗ 23.75 ± 3.23 23.52 ± 7.82 0.953
Weight of fat collection (g)∗ 12.12 ± 2.57 52.46 ± 21.62 0.014
Number of ASCs isolation (P0) (×106 cells)∗ 3.94 ± 3.73 3.79 ± 1.75 0.602‡
Number of ASCs (P0) per weight (×104 cells/g)∗ 33.39 ± 30.54 8.94 ± 7.34 0.047‡
Incubation time to P2 (days)∗ 18.40 ± 5.50 19.80 ± 8.04 0.833‡
ASCs markers
Positive markers
CD 73 (%)∗ 99.69 ± 0.26 99.60 ± 0.26 0.591
CD 90 (%)∗ 91.43 ± 10.79 93.85 ± 6.71 0.917‡
CD 105 (%)∗ 90.63 ± 9.49 87.85 ± 19.79 0.917‡
Negative markers
CD 34 (%)∗ 1.24 ± 1.54 1.46 ± 2.22 0.917‡
CD 45 (%)∗ 0.17 ± 0.08 0.16 ± 0.12 0.882
HLA-DR (%)∗ 0.55 ± 0.69 1.08 ± 2.01 0.834‡
Colony-forming units (/100 cells)∗ 3.13 ± 1.71 3.99 ± 1.52 0.428
Size of CFU (mm2)∗ 9.91 ± 4.72 12.99 ± 3.26 0.263
∗Mean ± SD. †Fisher’s exact test. ‡Mann-Whitney 𝑈 test.
The baseline characteristics of SC participants are showed
in Table 3. Patient’s age ranged from 16 to 48 years, with BMI
ranging from 17.70 to 36.29 kg/m2. SC tissuewasmeasured for
weight (range 28.30–75.85 g) and for yield for cell extraction
(range 3.49 × 104–21.76 × 104 cell/g). Mean time for cell
culture from 0th passage to 2nd passage was 19.80 ± 8.04 days
(range 14–33 days).
In comparison of ASC properties between IPFP and SC
source, this study found nonstatistical significance in gender
and BMI of participants both groups (𝑝 value = 1.000 and 𝑝
value = 0.953, resp.) but the mean age in SC group was lower
than IPFP group (𝑝 value = 0.001). The weight of adipose
tissue from lipoaspiration was more than TKA operation
(52.46±21.62, 12.12±2.57 g; 𝑝 value = 0.014).The number of
ASCs isolated from each source was not statistically different
(𝑝 value = 0.602) but IPFP group had significantly higher
yield of ASCs collection than other groups (33.39 ± 30.54
and 8.94 ± 7.34; 𝑝 value = 0.047). There was no statistically
significant difference in the time for ASC cultures to reach
2nd passage between groups (𝑝 value = 0.833), as shown in
Table 4.
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Figure 1: Flow cytometry of IPFP-ASCs (Case number 4). First row showed positive markers (CD 90, CD 105, and CD 73) and second row
showed negative markers (CD 34, CD 45, and HLA-DR).
3.2. ASCs Immunophenotypes. The phenotype of ASCs was
similar between groups as assessed by flow cytometry.
Positive markers for ASCs were shown by CD 73, CD 90, and
CD 105. Negative markers for ASCs were shown by CD 34,
CD 45, and HLA-DR (Table 3 and Figure 1).
3.3. Colony-Forming Unit Evaluation. CFU counting was
performed after 14 days of culture in polypropylene 6-well
plates (Figure 2). IPFP-ASCs had fewer CFUs (3.13±1.71 and
3.99 ± 1.52 CFUs per 100 cells) which were smaller than SC-
ASCs (9.91±4.72 and 12.99±3.26mm2) but this did not reach
statistical significance (𝑝 value = 0.428 and 0.263, resp.), as
showed in Table 4.
3.4. Safety Assessment. There was no evidence of bacterial or
other pathogen contaminations in culture. PCR formycobac-
terium and mycoplasma detection was all negative. Normal
cell karyotypes were evaluated (Figure 3).
3.5. ASCs Differentiation and Histology. The morphology of
ASCs was assessed using light microscopy prior to induction
of differentiation. ASCs appeared as flat polygonal cells.
Following differentiation cells were stained using appropri-
ate specific staining solutions with positive staining seen
Figure 2: CFU of IPFP-ASCs (Case number 4) under light micro-
scope (magnifier 4x). Dashed line was drawn along border of CFU
for size calculation by ImageJ software.
following osteogenic, adipogenic, and chondrogenic differen-
tiation (Figures 4–6).
3.6. Gene Expression of ASCs. IPFP-ASCs showed signifi-
cantly higher expression of SOX-9 (6.19 ± 5.56- and 0.47 ±
0.62-fold; 𝑝 value = 0.047) and RUNX-2 (17.33 ± 10.80- and
1.56 ± 1.31-fold;𝑝 value = 0.030) than SC-ASCs using theΔCT
formula (2−ΔΔCT) (Figure 7(a)). Furthermore, the expression
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Figure 3: Normal karyotype of IPFP-ASCs (46, XX).
(a) (b)
Figure 4: (a) IPFP-ASCs and (b) SC-ASCs morphology at 7th day of 2nd passage under light microscope (4x).
(a) (b)
(c) (d)
Figure 5: ASCs differentiation to adipocyte from IPFP (a) and SC (b) which stained by Oil Red-O (20x). Osteogenic differentiation to from
IPFP (c) and SC (d) which staining by Alizarin Red (20x).
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Figure 6: ASCs differentiation to chondrocyte from IPFP and SC
which stained by Alcian Blue. Both groups showed blue staining of
the spheroid of chondrocyte.
of PPAR-𝛾 by IPFP-ASCs was not significantly higher than
SMSCs (3,404.40 ± 2,763.47- and 1,335.33 ± 1,190.28-fold; 𝑝
value = 0.163) (Figure 7(b)).
4. Discussion
The implantation of MSCs holds great promise as a strategy
to improve bone and cartilage regeneration.The “cellular sub-
strate” represents one aspect of the tissue engineering triad,
with MSCs considered the principal progenitors of several
musculoskeletal tissues. It has been reported that this cell type
can be isolated from several tissues [6]. Adipose tissue ismore
accessible than bone marrow. However, the previous studies
have demonstrated that there are considerable differences
in growth and differentiation between different sources of
MSCs [33, 34]. Because of the accessibility of adipose tissue,
further investigation should focus on how this cell type
might be utilized effectively. Moreover, MSCs derived from
adipose tissues have been shown to be more effective in their
multipotent potential compared to other sources. ASCs had
lowpopulation doubling time for cell proliferation andhigher
antiapoptosis potential than mesenchymal cells derived from
bone marrow and cartilage [14].
This study focused on ASCs isolated from 2 different
sources, namely, subcutaneous tissue (SC) and infrapatellar
fat pad (IPFP). ASCs’ sterility and karyotype were evaluated
in this study as safety is a key consideration in regenerative
therapies. There was no contamination during the process of
cell isolation and culture expansion. With respect to general
morphology, cells isolated from both sources exhibited a
fibroblast liked appearance and plasticity without signifi-
cant differences. This study found that IPFP-ASCs and SC-
ASCs had similar cell surface profiles demonstrated by flow
cytometry including positive expression of CD 73, CD 90,
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Figure 7: (a) Comparison of SOX-9 and RUNX-2 expression in
IPFP-ASCs and SC-ASCs. (b) Comparison of PPAR-𝛾 expression in
IPFP-ASCs and SC-ASCs. ∗𝑝-value < 0.05 and ∗∗𝑝-value < 0.01.
and CD 105 and negative expression of CD 34, CD 45,
and HLA-DR. Their proliferation potentials were evaluated
using clonogenic assay by number and size of CFUs. We
observed no differences between both groups. With respect
to differentiation ability, IPFP-ASCs showed superiority in
osteogenic and chondrogenic differentiation over SC-ASCs
as assessed by SOX-9 and RUNX-2 expression representing
chondrogenic differentiation and osteogenic differentiation,
respectively. Thus, we conclude from this in vitro study that
the infrapatellar fat pad may be a good candidate source for
cartilage and bone regeneration.
The IPFP is an intracapsular and extrasynovial store
of adipose tissue located between the patellar tendon, the
femoral condyle, and the tibial plateau [25]. The IPFP has
previously been identified as a minimally invasive and easily
accessible source of ASCs that can be obtained safely by
orthopaedic surgeons using an arthroscopic approach with
minimalmorbidity [28, 35]. Conventionally, subcutaneous fat
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has been obtained using lipoaspiration with a key advantage
being the large volumes of tissue that can be obtained in
this way. However, lipoaspiration is associated with com-
plications such as scarring, surface irregularities or skin
necrosis, seroma, hematoma, allergic reactions to drugs, skin
discoloration, temporary bruising, numbness or nerve injury,
and temporary adverse drug reaction [36]. Although the total
number of cells harvested from IPFPwasmore than SC in this
study, when normalized by tissueweight, the number of ASCs
isolated from the IPFP was significantly higher than from SC.
Anatomical area from which tissue is isolated may affect
gene expression. IPFP is in close contact with synovial
membrane and synovial fluid; this microenvironment may
affect the characteristics of contained ASCs. Bobacz et al.
demonstrated that growth differentiation factor 5 (GDF-
5 or cartilage derived morphogenic protein 1) and BMP-
7 (osteogenic protein 1) were expressed in higher levels
in synovial tissue than articular cartilage [37] potentially
increasing the chondrogenic differentiation of IPFP-ASCs.
Our findings that SOX-9, RUNX-2, and PPAR-𝛾 expression is
higher in IPFP-ASCs than SC-ASCs is in keepingwith Lopa et
al.These authors found that IPFP-ASCs had lower expression
of the hypertrophic and fibrogenic markers COL10A1 and
COL1A1 [29]. As a result, we feel that IPFP-ASCsmay provide
a cellular substrate capable of high quality chondrogenesis in
cartilage therapy.
A limitation of the present study was a lack of paired
samples of IPFP and SC from individual donors. This was
not possible due to ethical considerations. Differences in
age between groups may have influenced the biological
characteristics of tissue and cells. Previous studies have not
found any influence of gender on ASCs characteristics by
expression of cell surface markers such as CD 34, CD 44,
CD 45, CD 54, CD 73, CD 80, CD 90, CD 105, CD 106,
and CD 166 [38]. Similarly, Scharstuhl et al. reported that
there was no correlation betweenmRNA expression for types
1 and 2 collagen and donor age in bone marrow-derived
mesenchymal stem cell from 98 osteoarthritis patients [39].
Choudhery et al. reported no difference between adipogenic
(PPAR-𝛾 and lipoprotein lipase) and neurogenic (neuro-
filament and neuron-specific-enolase) gene expression of
SC-ASCs compared in patients from groups of different
ages [40]. Khan et al. reported that there was no difference
in osteogenic differentiation potential of IPFP-ASCs and
expression of alkaline phosphatase and osteocalcin expres-
sion between patient groups: mean age 57± 3 years group and
86 ± 3 years group [41].
Accordingly, ASCs from the infrapatellar fat pad may be
considered good alternative source of ASCs because of their
expression of chondrogenic and osteogenic genes. Further
investigations in which IPFP-ASCs are evaluated in an animal
model setting are now required to evaluate clinical outcomes
such as quality of IPFP-ASCs induced cartilage and cartilage
transplantation technique.
5. Conclusion
IPFP represents a good alternative source for MSCs to
conventional SC-derived cells. General characteristics were
similar between IPFP-ASCs and SC-ASCs but gene expres-
sions for differentiation to a chondrogenic and osteogenic
lineage were higher within IPFP-derived cells. IPFP should
be considered a high quality source for bone and cartilage
regeneration therapy.
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